We are Sorry, This Page doesn't Exist
Durham drugmaker pushes forward with its latest clinical cancer treatment
Riding on the momentum of its recent initial public offering, a Triangle gene therapy company is launching its second potential cancer treatment into clinical trials......»»
uniQure presents clinical data from phase III HOPE-B gene therapy trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Gene therapy company"s proxy fight comes down to the wire
The company, which last month disclosed that one patient in a clinical trial went blind in the eye treated with its gene therapy, is now in a nasty tug-of-war for control of its board......»»
UniQure stock is up after FDA lifts clinical hold on experimental gene therapy
Shares of UniQure gai.....»»
uniQure announces removal of clinical hold on hemophiilia B gene therapy program
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
UniQure"s Stock Is Trading Higher As FDA Lifts Clinical Hold On Its Hemophilia B Gene Therapy Program
read more.....»»
uniQure says hemophilia B gene therapy program placed on clinical hold
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
OHSU"s HIV vaccine nears clinical trial
A promising HIV vaccine developed at Oregon Health & Science University is getting closer to human clinical trials. Dr. Louis Picker, a professor at OHSU’s Vaccine & Gene Therapy Institute, said his lab has tested a weakened version of the vaccin.....»»
Krystal Biotech Rallies On Positive Trial Results For Skin Condition
Krystal Biotech Inc (NASDAQ: KRYS) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday. The stock was higher by 46.11% at $42.59 at the time of publication Monday. read more.....»»
Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis
Novartis (NVS) signs a contract to purhcase the U.S. based clinical stage gene therapy company, AveXis, Inc for a cash-tender offer of $218 per share. Novartis NVS announce.....»»
Nationwide Children"s gene therapy spinoff inks option to be acquired by Sarepta
Sarepta Therapeutics Inc. has invested up to $105 million in the latest gene therapy spinoff from Nationwide Children's Hospital – and signed an option to acquire the company for an undisclosed but higher amount if clinical trial results are promis.....»»
Sarepta shares rocket 55% on positive early results for DMD gene therapy
Sarepta Therapeutics Inc. shares rocketed 55.6% in extremely heavy Tuesday morning trade after the company reported positive early results from a phase 1/2a gene therapy clinical trial for three patients with the rare.....»»
Sarepta shares rocket 50% on promising early results for DMD gene therapy
Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right......»»
Sarepta shares rocket 40% on promising early results for DMD gene therapy
Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right......»»
3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy
Uniqure NV (NASDAQ: QURE), a gene therapy company that focuses on severe unmet medical needs, could "dominate" the space with its AMT-061 therapy, according to B. Riley FBR. Latest Ratings for QURE DateFirmA.....»»
Gene therapy startup SQZ heads to clinical trials after $72M Series C round
Following the closure of a $72 million Series C funding round on Wednesday, Watertown startup SQZ Biotechnologies plans to launch clinical trials within the next year on a gene therapy. Its CEO contends it could go further and work faster than anythi.....»»
Novartis-owned firm picks Durham over Illinois, Ireland
AveXis, a clinical stage gene therapy company, has tapped Durham County over Illinois and Ireland for a major expansion, one that involves 200 production jobs. Average wages are expected to be $72,952, above Durham's county average of $68,731. The co.....»»
Novartis-owned firm picks NC over Illinois, Ireland
AveXis, a clinical stage gene therapy company, has tapped Durham County over Illinois and Ireland for a major expansion, one that involves 200 production jobs. Average wages are expected to be $72,952, above Durham's county average of $68,731. The co.....»»
In major cell therapy manufacturing deal, UCSF, biotech tools leader Thermo Fisher go small to go big
The new cell therapy manufacturing facility, which will open early next year, will be able to deliver highly specialized cell therapies to patients in clinical trials at UCSF's women's, children's and cancer hospitals complex across Mariposa Street......»»
Passage Bio co-founders launch new company with $200M to fund gene therapies coming out of Penn
The company's founders are the director of Penn's gene therapy program and the former head of research and development at GlaxoSmithKline......»»